Identification of Stevens–Johnson syndrome and toxic epidermal necrolysis in electronic health record databases
- 24 April 2015
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 24 (7) , 684-692
Abstract
Background: Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) carry a high mortality risk. While identifying clinical and genetic risk factors for these conditions has been hindered by their rarity, large electronic health databases hold promise for identifying large numbers of cases for study, especially with the introduction in 2008 of ICD‐9 codes more specific for these conditions.Objective: The objective of this study is to estimate the validity of ICD‐9 codes for ascertaining SJS/TEN in 12 collaborating research units in the USA, covering almost 60 million lives.Methods: From the electronic databases at each site, we ascertained potential cases of SJS/TEN using ICD‐9 codes. At five sites, a subset of medical records was abstracted and standardized criteria applied by board‐certified dermatologists to adjudicate diagnoses. Multivariate logistic regression was used to identify factors independently associated with validated SJS/TEN cases.Results: A total of 56 591 potential cases of SJS/TEN were identified. A subset of 276 charts was selected for adjudication and 39 (of the 276) were confirmed as SJS/TEN. Patients with the ICD‐9 codes introduced after 2008 were more likely to be confirmed as cases (OR 3.32; 95%CI 0.82, 13.47) than those identified in earlier years. Likelihood of case status increased with length of hospitalization. Applying the probability of case status to the 56 591 potential cases, we estimated 475–875 to be valid SJS/TEN cases.Conclusion: Newer ICD‐9 codes, along with length of hospitalization, identified patients with a high likelihood of SJS/TEN. This is important for identification of subjects for future pharmacogenomics studies. Copyright © 2015 John Wiley & Sons, Ltd.Keywords
Funding Information
- FDA (HHSF223201000009I)
This publication has 19 references indexed in Scilit:
- Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in TaiwanNew England Journal of Medicine, 2011
- HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in EuropeansNew England Journal of Medicine, 2011
- Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese populationHuman Molecular Genetics, 2010
- HLA‐B* 1502 screening: Time to clinical practiceEpilepsia, 2010
- Association between HLA‐B*1502 and carbamazepine‐induced severe cutaneous adverse drug reactions in a Thai populationEpilepsia, 2010
- Association of HLA-BFNx011502 allele and carbamazepine-inducedStevens-Johnson syndromeamong IndiansIndian Journal of Dermatology, Venereology and Leprology, 2009
- Drug-Induced Skin, Nail and Hair DisordersDrug Safety, 2007
- A marker for Stevens-Johnson syndrome …: ethnicity mattersThe Pharmacogenomics Journal, 2006
- Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal NecrolysisNew England Journal of Medicine, 1995
- Using a claims database to investigate drug‐induced Stevens‐Johnson syndromeStatistics in Medicine, 1991